PLXHealthcare · BiotechnologyPLX Stock Forecast: Protalix Biotherapeutics, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Protalix Biotherapeutics, Inc. hold a median 12-month price target of $11 — +374.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 1 Aug 2026 — in the upper half.
PLX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Protalix Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Protalix Biotherapeutics, Inc. — and when they’d sell — is the membership.
PLX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +374.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Protalix Biotherapeutics, Inc. (PLX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 12.2×
- Price / sales
- 2.4×
- Price / book
- 2.8×
- EV / EBITDA
- 7.0×
Cheaper than 54% of US stocks
Cheaper than 47% of US stocks
Cheaper than 36% of US stocks
Cheaper than 49% of US stocks
- Revenue growth (YoY)
- 233.7%
- Earnings growth (YoY)
- 233.7%
- Gross margin
- 87.8%
- Operating margin
- 62.7%
- Net margin
- 20.1%
Higher than 97% of US stocks
Higher than 92% of US stocks
Higher than 96% of US stocks
Higher than 99% of US stocks
Higher than 82% of US stocks
- Return on equity
- 27.3%
- Return on assets
- 14.0%
- Dividend yield
- —
Higher than 87% of US stocks
Higher than 96% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PLX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLX appears on the weeks it earns a place.
Frequently asked questions about PLX stock
What is the PLX stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Protalix Biotherapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PLX stock a buy right now?
Of the 1 analysts covering Protalix Biotherapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protalix Biotherapeutics, Inc. 67 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PLX?
As at 1 Aug 2026, Protalix Biotherapeutics, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
Will PLX stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +374.1% from the last close, and Ticker Nerd's factor model ranks Protalix Biotherapeutics, Inc. 67 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PLX stock forecast for 2030?
No analyst covering Protalix Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $12 over the next 12 months.
How has PLX stock performed over the past year?
Protalix Biotherapeutics, Inc. returned +60.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Protalix Biotherapeutics, Inc. do?
Protalix Biotherapeutics Inc. is a biopharmaceutical company focused on developing and manufacturing therapeutic proteins using its proprietary plant cell-based expression system.
About Protalix Biotherapeutics, Inc.
Protalix Biotherapeutics Inc. is a biopharmaceutical company focused on developing and manufacturing therapeutic proteins using its proprietary plant cell-based expression system. This innovative platform allows for the production of recombinant proteins, offering advantages such as scalability and cost-effectiveness compared to traditional mammalian cell culture methods. Protalix is prominently engaged in advancing solutions within the rare diseases sector, exemplifying its commitment to addressing unmet medical needs. One of its leading products targets Gaucher disease, a hereditary enzyme deficiency disorder. Serving global pharmaceutical markets, Protalix collaborates with international partners to commercialize and distribute its therapies. The company’s research and development efforts emphasize expanding the therapeutic potential of its platform, thereby contributing significantly to the biotechnology industry. Based in the biotechnology hub of Israel, Protalix Biotherapeutics Inc. plays an important role in the biopharmaceutical field, pushing the horizons of innovative treatment options and impacting the healthcare sector by striving to improve patient outcomes for rare, genetic conditions.
CEO Mr. Dror Bashan · 226 employees · United States · https://www.protalix.com